{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:28:53Z","timestamp":1789687733612,"version":"4.0.1"},"reference-count":28,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"unspecified","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000276","name":"Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002141","name":"Public Health England","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012095","name":"Scottish Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012095","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Northern Ireland Government"},{"DOI":"10.13039\/100015846","name":"Llywodraeth Cymru","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015846","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n<jats:title>Introduction<\/jats:title>\n<jats:p>Understanding the effectiveness and durability of protection against SARS-CoV-2 infection conferred by previous infection and COVID-19 is essential to inform ongoing management of the pandemic. This study aims to determine whether prior SARS-CoV-2 infection or COVID-19 vaccination in healthcare workers protects against future infection.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods and analysis<\/jats:title>\n<jats:p>This is a prospective cohort study design in staff members working in hospitals in the UK. At enrolment, participants are allocated into cohorts, positive or na\u00efve, dependent on their prior SARS-CoV-2 infection status, as measured by standardised SARS-CoV-2 antibody testing on all baseline serum samples and previous SARS-CoV-2 test results. Participants undergo monthly antibody testing and fortnightly viral RNA testing during follow-up and based on these results may move between cohorts. Any results from testing undertaken for other reasons (eg, symptoms, contact tracing) or prior to study entry will also be captured. Individuals complete enrolment and fortnightly questionnaires on exposures, symptoms and vaccination. Follow-up is 12 months from study entry, with an option to extend follow-up to 24 months.<\/jats:p>\n<jats:p>The primary outcome of interest is infection with SARS-CoV-2 after previous SARS-CoV-2 infection or COVID-19 vaccination during the study period. Secondary outcomes include incidence and prevalence (both RNA and antibody) of SARS-CoV-2, viral genomics, viral culture, symptom history and antibody\/neutralising antibody titres.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Ethics and dissemination<\/jats:title>\n<jats:p>The study was approved by the Berkshire Research Ethics Committee, Health Research Authority (IRAS ID 284460, REC reference 20\/SC\/0230) on 22 May 2020; the vaccine amendment was approved on 12 January 2021. Participants gave informed consent before taking part in the study.<\/jats:p>\n<jats:p>Regular reports to national and international expert advisory groups and peer-reviewed publications ensure timely dissemination of findings to inform decision making.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Trial registration number<\/jats:title>\n<jats:p>\n<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT11041050\">NCT11041050<\/jats:ext-link>.<\/jats:p>\n<\/jats:sec>","DOI":"10.1136\/bmjopen-2021-054336","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T12:26:40Z","timestamp":1669724800000},"page":"e054336","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":44,"title":["Impact of prior SARS-CoV-2 infection and COVID-19 vaccination on the subsequent incidence of COVID-19: a multicentre prospective cohort study among UK healthcare workers \u2013 the SIREN (Sarscov2 Immunity &amp; REinfection EvaluatioN) study protocol"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct11041050","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1053-2521","authenticated-orcid":false,"given":"Sarah","family":"Wallace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7154-0432","authenticated-orcid":false,"given":"Andre","family":"Charlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6904-0500","authenticated-orcid":false,"given":"Peter D","family":"Kirwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Gillson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Atti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Timeyin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Foulkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Taylor-Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2069-2684","authenticated-orcid":false,"given":"Nick","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhumita","family":"Shrotri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakib","family":"Rokadiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanche","family":"Oguti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amoolya","family":"Vusirikala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Zambon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3783-1284","authenticated-orcid":false,"given":"Tim J G","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Ramsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin S","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Chand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5179-5702","authenticated-orcid":false,"given":"Susan","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,6,28]]},"reference":[{"key":"2022112903181775000_12.6.e054336.1","unstructured":"Government of the Hong Kong Special Administrative Region . CHP closely monitors cluster of pneumonia cases on mainland 31\/12\/2019. Available: https:\/\/www.info.gov.hk\/gia\/general\/201912\/31\/P2019123100667.htm [Accessed 12 Jan 2022]."},{"key":"2022112903181775000_12.6.e054336.2","unstructured":"World Health Organization Regional Office for Europe . Who announces COVID-19 outbreak a pandemic, 2020. Available: https:\/\/www.euro.who.int\/en\/health-topics\/health-emergencies\/coronavirus-covid-19\/news\/news\/2020\/3\/who-announces-covid-19-outbreak-a-pandemic [Accessed 12 Jan 2022]."},{"key":"2022112903181775000_12.6.e054336.3","unstructured":"World Health Organization . Who coronavirus (COVID-19) Dashboard. Available: https:\/\/covid19.who.int\/ [Accessed 13 Feb 2022]."},{"key":"2022112903181775000_12.6.e054336.4","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/cid\/ciaa1330","article-title":"Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain","volume":"73","author":"Van Elslande","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022112903181775000_12.6.e054336.5","doi-asserted-by":"crossref","first-page":"e2946","DOI":"10.1093\/cid\/ciaa1275","article-title":"Coronavirus disease 2019 (COVID-19) re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain confirmed by whole genome sequencing","volume":"73","author":"To","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022112903181775000_12.6.e054336.6","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(20)30910-5","article-title":"A case of SARS-CoV-2 reinfection in Ecuador","volume":"21","author":"Prado-Vivar","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2022112903181775000_12.6.e054336.7","doi-asserted-by":"crossref","first-page":"e2827","DOI":"10.1093\/cid\/ciaa1436","article-title":"A case of early reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"73","author":"Larson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022112903181775000_12.6.e054336.8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S1473-3099(20)30764-7","article-title":"Genomic evidence for reinfection with SARS-CoV-2: a case study","volume":"21","author":"Tillett","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2022112903181775000_12.6.e054336.9","doi-asserted-by":"crossref","first-page":"e2823","DOI":"10.1093\/cid\/ciaa1451","article-title":"Asymptomatic reinfection in two healthcare workers from India with genetically distinct SARS-CoV-2","volume":"73","author":"Gupta","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022112903181775000_12.6.e054336.10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2021.09.019","article-title":"Serological profile of first SARS-CoV-2 reinfection cases detected within the siren study","volume":"84","author":"Atti","year":"2022","journal-title":"J Infect"},{"key":"2022112903181775000_12.6.e054336.11","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00675-9"},{"key":"2022112903181775000_12.6.e054336.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00575-4"},{"key":"2022112903181775000_12.6.e054336.13","doi-asserted-by":"crossref","first-page":"100861","DOI":"10.1016\/j.eclinm.2021.100861","article-title":"SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy","volume":"35","author":"Abu-Raddad","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2022112903181775000_12.6.e054336.14","doi-asserted-by":"publisher","DOI":"10.1093\/CID\/CIAB234"},{"key":"2022112903181775000_12.6.e054336.15","doi-asserted-by":"crossref","unstructured":"Hall V , Foulkes S , Insalata F . Effectiveness and durability of protection against future SARS-CoV-2 infection conferred by COVID-19 vaccination and previous infection; findings from the UK siren prospective cohort study of healthcare workers March 2020 to September 2021. MedRxiv 2021.doi:10.1101\/2021.11.29.21267006","DOI":"10.1101\/2021.11.29.21267006"},{"key":"2022112903181775000_12.6.e054336.16","doi-asserted-by":"crossref","unstructured":"Andrews N , Tessier E , Stowe J . Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. MedRxiv 2021.doi:10.1101\/2021.09.15.21263583","DOI":"10.1101\/2021.09.15.21263583"},{"key":"2022112903181775000_12.6.e054336.17","doi-asserted-by":"crossref","unstructured":"Aldridge RW , Yavlinsky A , Nguyen V . Waning of SARS-CoV-2 antibodies targeting the spike protein in individuals post second dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and risk of breakthrough infections: analysis of the virus Watch community cohort. MedRxiv 2021.doi:10.1101\/2021.11.05.21265968","DOI":"10.1101\/2021.11.05.21265968"},{"key":"2022112903181775000_12.6.e054336.18","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","article-title":"Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans","volume":"5","author":"Seow","year":"2020","journal-title":"Nat Microbiol"},{"key":"2022112903181775000_12.6.e054336.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2114583"},{"key":"2022112903181775000_12.6.e054336.20","unstructured":"World Health Organization Headquarters . Enhancing response to omicron SARS-CoV-2 variant: technical brief and priority actions for member states, 2022. Available: https:\/\/www.who.int\/publications\/m\/item\/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states [Accessed 13 Jan 2022]."},{"key":"2022112903181775000_12.6.e054336.21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.633184"},{"key":"2022112903181775000_12.6.e054336.22","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-215414"},{"key":"2022112903181775000_12.6.e054336.23","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1017\/ice.2020.402","article-title":"Seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a London NHS trust","volume":"42","author":"Grant","year":"2021","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2022112903181775000_12.6.e054336.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31484-7"},{"key":"2022112903181775000_12.6.e054336.25","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(20)30164-X"},{"key":"2022112903181775000_12.6.e054336.26","unstructured":"Public health England, University of Oxford, Oxford university hospitals. evaluation of sensitivity and specificity of four commercially available SARS-CoV-2 antibody immunoassays. London, 2020. Available: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/898437\/Evaluation__of_sensitivity_and_specificity_of_4_commercially_available_SARS-CoV-2_antibody_immunoassays.pdf [Accessed 13 Jan 2022]."},{"key":"2022112903181775000_12.6.e054336.27","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1177\/0962280217708671","article-title":"Bayesian cure rate models induced by frailty in survival analysis","volume":"26","author":"de Souza","year":"2017","journal-title":"Stat Methods Med Res"},{"key":"2022112903181775000_12.6.e054336.28","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v038.i07"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-054336","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T12:27:05Z","timestamp":1669724825000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-054336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,28]]},"published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1136\/bmjopen-2021-054336"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-054336","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}